Physician profile
Ashley E Davis
NPI 1396230504
$2,431.27
in general payments reported to CMS, 2019-2025
23 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $572 · 2023: $720 · 2024: $1,016 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,859.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $567.21 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $340.44 | 2022-2025 | Verquvo |
| Merz North America, INC. | $253.75 | 2022 | |
| Kestra Medical Technology Services, INC. | $169.21 | 2023-2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.92 | 2023-2025 | Lifevest |
| Amgen INC. | $114.62 | 2022-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $108.97 | 2022-2024 | Brilinta, Lokelma |
| Janssen Pharmaceuticals, INC | $108.45 | 2022-2024 | Xarelto |
| Pfizer INC. | $101.12 | 2023-2024 | |
| Boston Scientific Corporation | $90.86 | 2024-2025 | Watchman Flx, Varithena Administration Pack |
| E.R. Squibb & Sons, L.L.C. | $71.09 | 2022-2024 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $65.12 | 2023 | |
| Medtronic, INC. | $47.38 | 2022-2024 | Linq II, Micra |
| Lexicon Pharmaceuticals, INC. | $40.84 | 2023 | Inpefa |
| Philips North America LLC | $38.58 | 2024 | (Ck4) Mcot |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $34.07 | 2022-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.09 | 2024 | Jardiance |
| Daiichi Sankyo INC. | $24.65 | 2024 | Injectafer |
| Amarin Pharma, INC. | $23.27 | 2022 | |
| United Therapeutics Corporation | $19.03 | 2023 | Tyvaso, Orenitram |
| Baxter Healthcare | $18.79 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $17.87 | 2025 | Ozempic, Rybelsus |
| Kowa Pharmaceuticals America, INC. | $12.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.